Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial

IMPORTANCE: Isocitrate dehydrogenase 1 (IDH1) variations occur in up to approximately 20% of patients with intrahepatic cholangiocarcinoma. In the ClarIDHy trial, progression-free survival as determined by central review was significantly improved with ivosidenib vs placebo. OBJECTIVE: To report the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Andrew X., Macarulla, Teresa, Javle, Milind M., Kelley, R. Kate, Lubner, Sam J., Adeva, Jorge, Cleary, James M., Catenacci, Daniel V. T., Borad, Mitesh J., Bridgewater, John A., Harris, William P., Murphy, Adrian G., Oh, Do-Youn, Whisenant, Jonathan R., Lowery, Maeve A., Goyal, Lipika, Shroff, Rachna T., El-Khoueiry, Anthony B., Chamberlain, Christina X., Aguado-Fraile, Elia, Choe, Sung, Wu, Bin, Liu, Hua, Gliser, Camelia, Pandya, Shuchi S., Valle, Juan W., Abou-Alfa, Ghassan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461552/
https://www.ncbi.nlm.nih.gov/pubmed/34554208
http://dx.doi.org/10.1001/jamaoncol.2021.3836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461552/
https://www.ncbi.nlm.nih.gov/pubmed/34554208
http://dx.doi.org/10.1001/jamaoncol.2021.3836

Ejemplares similares